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Abstract 
Introduction: In vitro drug sensitivity relies on the growth of plasmodium in the presence of the antimalarials. 
These fresh isolates brought in for assay from collection sites normally not near the laboratory require a medium 
to keep the parasites viable in order to produce results which are a representation of the field situation in terms of 
drug susceptibility. Methods: This study validated the use of a formulated transport medium (TM) by assaying 
322 Plasmodium falciparum field isolates from patients visiting Chulaimbo sub county hospital in Maseno 
division, for 50% inhibitory concentrations (IC50) against four antimalarials using SYBR Green 1 in vitro assay. 
These samples were transported using a formulated transport medium (TM) and the conventional EDTA 
anticoagulant tubes to act as control.Results: Similarity was detected with no significant difference (P >0.05) 
observed in the medians inhibitory concentration 50 (IC50) between samples in the EDTA anticoagulant and TM. 
However, dihydroartemisinin (DHA) which showed to have a correlation significance (p<0.05) with most of the 
drugs used, Conclusion: Variations in correlations between the pairs of drugs calls for more research to expound 
on this finding. Otherwise, similarity between the two anticoagulants its warrants continued use. 
 
INTRODUCTION 
In Kenya, malaria continues to cause significant morbidity and mortality, and is often a location where drug 
resistance emerges in Africa. The development of Plasmodium. falci parum resistance to chloroquine 
diphosphate (CQ),  and later sulfadoxine-pyrimethamine, are  well described (Mwai et al., 2009; Khan et al., 
1997).  This warrants continued in vitro drug IC50 monitoring of P. falciparum field isolates, which is becoming 
more practical and safer, as more  reliable  assays like SYBR  Green I become  established, combined with 
simpler field isolate processing such as “immediate ex vivo” (IEV) (Akala et al., 2011).SYBR green 1 in vitro 
technique is the latest technique which is convenient and can be used in a large parasite density and produces 
rapid reproducible results (Rengarajan et al., 2002). Its measure of sensitivity depends on the growth of parasites 
subjected to antimalarials in a medium.  
Lack of in vitro plasmodial growth has been attributed to; the effects of a markedly diminished viability 
of all parasite populations within the same isolate leading to death of the parasites before reaching the laboratory 
(Basco, 2004), very low starting parasitaemia due to poor survival rates of the parasites from the field (Bacon et 
al., 2007), or presence of trace amounts of antimalarial drugs or intake of traditional medicine undetected by 
urine test (Basco, 2003). Low yield of the in vitro assay was also observed in a Nigerian study and may have 
been due to suboptimal storage and transportation conditions of parasitized blood or due to the presence of traces 
of the drug in the sample rather than limitations of the technical approach (Issaka et al., 2013). So to enhance the 
immediate survival and later growth of these parasites, there is need for a proper transition from the natural host 
(human) to the artificial medium which will subsequently be used for transportation to the laboratory. 
Apart from the medium the parasites are exposed to, parasites growth rates sometimes depend on the 
source of the serum used. For instance, diet, medication consumed, the state of health, and the immune status of 
a donor can inadvertently affect growth rates and modify the 50% inhibitory concentration results (ofulla et al., 
1994). The presence of trace amounts of antimalarial drugs or intake of traditional medicine undetected by urine 
test for commonly used antimalarial drugs may partially explain why some fresh isolates do not grow in vitro 
(Basco, 2003). Furthermore, serum may contain unknown quantities of drug-binding proteins that can skew IC50 
values. For maximum plasmodial growth, it is important eliminating all these host immune components before 
test, so as to render maximum growth of the parasites in the antimalarials, thus, making it reliable especially for 
fresh clinical isolates meant for epidemiological studies (Russell et al., 2003). 
In that regard, this study employed the use of a formulated transport media (TM) with an aim of trying 
to improve on the viability of parasites during transportation to the lab for further cultivation. Infected blood 
samples were asceptically put in the tubes with TM and transported to the laboratory alongside with the samples 
put in the EDTA anticoagulant tubes. In the laboratory, these samples (in TM and EDTA) were washed twice 
using complete medium by centrifugation as a simple pretest procedure to remove antimalarial immune plasma, 
white blood cells, and residual drugs which may be present in the test blood, before subjecting it to the drugs. 
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The IC50 results obtained were compared with the IC50 results obtained from samples collected using the EDTA 
coated tubes, an anticoagulant which has the advantages of a lack of inhibitory action on DNA allowing the best 
preservation of cellular components and morphology of blood cells (Reardon et al., 1991), thus best for 
hematologic and biochemical investigations (Basco, 2004). This study was carried out in order to shed light on 
the importance of a medium with nutrients which can promote better transition and adaptation to enhance 
immediate survival, prolonged survival and viability of the plasmodium parasites once removed from the human 
host. 
 
Subjects and methods  
Protocol, sites, and subjects 
This study was approved by Jaramogi Oginga Odinga teaching and referral hospital Ethics and review committee 
(JOOTRH ERC) accreditation No. 01713.Participating clinical center was Chulaimbo sub county hospital 
located in Maseno division of Kisumu County. Training of the medical staffs especially those at the laboratory 
on the inclusion and exclusion criteria for subjects’ selection was done. Subjects attending outpatient clinic, who 
were at least 2years of age and having met the inclusion criteria (mono infection of p.falciparum with 
parasitaemia of between 1000 to 200,000asexual parasites /ul of blood) were invited to participate .Informed 
consent was obtained from adults subject (>18years of age) or legal guardians for subjects <18years of age. 
 
Sample collection and preparation 
Consented subjects provided 4ml of blood for transport to the laboratory. 2ml was collected in to a plain 
vacutainer tubes with 2ml of the formulated transport medium while the other 2ml was drawn into an EDTA 
coated vacutainer tubes. Both tubes were placed at 40c until transported to the lab at the close of the day   to 
begin immediate ex vivo (IEV) drug IC50   testing described below. SYBR Green 1based in vitro IC50 drug 
sensitivity described below was used to test each P.falciparum field isolate transported in the two anticoagulants 
against a panel of 4 antimalarials supplied as Artemether (ART), Lumefantrine (LU), Dihydroartemisinin (DHA) 
and piperaquine (PPQ). The test drugs were obtained from Kenya Medical Research Institute (KEMRI).To 
prepare the test drugs, solutions at 1mg/ml were prepared in 5ml  100% dimethyl sulfoxide for ART, LU, DHA 
and  PPQ. Further dilutions were in complete RPMI1640 media to the desired starting concentrations followed 
by two fold serial dilutions to generate 10 concentrations for IC50 testing (Mbaisi et al., 2004). The concentration 
ranges in ng/ml from highest to the lowest were; ART (200 to 0.0976), LU (200 to 0.0976), DHA (200 to 
0.0976) and PPQ (500 to 0.2441). The drug solutions were prepared and used immediately or stored at -800c for 
not longer than 1 month before use. Basic and complete RPMI 1640 culture media, the later with glucose and 
hypoxanthine enrichment were prepared as described (Johnson et al., 2007). Plasmodium falciparum isolates 
processed IEV were placed into assay within 8 hours of phlebotomy, without culture adaptation. These samples 
were first washed in RPMI 1640 by centrifugation at 2500revolutions per minute for 3minutes for three 
consecutive times. Blood samples with > 1% parasitemia were adjusted to1% parasitemia at 2% hematocrit using 
uninfected O+ erythrocytes, and those with ≤ 1% parasitemia were used unadjusted at 2% hematocrit. Transfer 
of parasite sample and antimalarial drug aliquots in complete RPMI 1640 drug aliquots onto 96-well 
microculture plates and addition of lysis buffer after 72 hours incubation was done as previously described 
(Johnson et al., 2007).The plates were then placed at room temperature in the dark, for 5–15 minutes.  Parasite 
replication inhibition was quantified and the IC50   for each drug calculated by an equation generating a 
sigmoidal concentration response curve (variable slope),  with  log  transformed drug  concentrations on  the  X 
axis and  relative  fluorescent units  (RFUs) on  the Y axis (Graphpad Prism for Windows, version  5.0; Graphpad 
Software, Inc., San Diego, CA). (Bacon et al., 2007). 
 
Statistical analysis 
Data were analysed by using Mann-Whitney test; a non parametric test which doesn’t assume a gaussian 
distribution, to compare the medians IC50 values of antimalarials in the two categories (EDTA and TM). Pearson 
correlation coefficient was also used to determine the r value which gave the possible correlation of the 
logarithmic values of IC50 between the antimalarials in each category. Data were analysed using GraphPad Prism 
5.00 for Windows; GraphPad Software, San Diego, CA, and Sigma Plot version 10; Systat Software, Inc., San 
Jose, CA). 
 
Results 
We assayed 322 P. falciparum field isolates from Chulaimbo sub county hospital against four panels of drugs 
namely ART, LUM, DHA and PPQ. These samples were brought in the EDTA anticoagulant and plain tubes 
with formulated TM from the hospital which is 20minutes drive to the laboratory. A successful assay result 
(defined as dose concentration relationship across the 10 drug dilutions for one or all drugs per field isolate) 
occurred in more than 50% of all the isolates in EDTA and TM. 70% of the assays had parasitaemia >0.5%. Few 
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plates gave high relative fluorescent units (RFU) for samples in both groups while more plates gave modarate 
RFU of between 4000-8000 parasites or even lower. However, their curves converged to create IC50 dose 
respose curves apart from few which didn’t and thus were excluded. From the in vitro assay (table 1), the median 
IC50 values in ng/ml obtained from the 322 samples transported using the EDTA anticoagulant were higher in 
three drugs (LU 5.409, DHA 2.567, and PPQ 7.887) than the median IC50 values obtained from the same 
samples in the TM (LU 4.007, DHA 1.691, and PPQ 6.911). While the median IC50 for ART in TM emerged 
higher than in EDTA with values of 4.887 and 4.275 respectively (table 1). However, this table further shows 
that the individual activity of these drugs didn’t differ significantly (P<0.05) for the two categories. Using Mann 
Whitney test, there was no significant difference (P = 0.9873) between the median IC50 values of samples 
exposed to ART in both EDTA and TM. Similarly, we observed no significant difference (P = 0.7448) in the 
samples subjected to LU when the two groups were compared. The least median IC50 values were experienced 
by samples treated with DHA (2.567 and 1.6911 for EDTA and TM respectively) while the highest IC50 values 
were experienced with the samples exposed to PPQ with medians of 7.887 and 6.911 for EDTA and TM 
respectively. Nevertheless, the activity of both antimalarials didn’t differ significantly with p=0.6839 and p= 
0.8153 for DHA and PPQ respectively. Comparison using their mean IC50 values gave no significant different 
(p>0.05) results for the drugs in both categories except for ART which showed a big significant decrease 
(p=0.0056) in mean IC50 for samples in the TM. The IC50 ranges for all the drugs were generally in the upper 
half of the IC50 range as shown in figure 1 below. 
A pearsons correlation coefficient analysis of the antimalarials was perfomed separately for the samples 
which were transported in EDTA and those in the TM. For the samples in the EDTA tube (table 2), the results 
showed that there was no correlation significance (p=0.3699, 0.2916 and 0.6364 respectively) between ART and 
LU, ART and PPQ and also between LUM and PPQ as indicated by their r values 0.04967, 0.0262 and 0.0584 
respectively. We observed a correlation significance (p=0.0259, 0.0122 and 0.0203) of Artemisinin derivatives 
ART and DHA, LUM and DHA, and DHA and PPQ with high r values of 0.1230, 0.1382 and 0.1281 
respectively. Among the samples in the TM, correlation significance (p<0.05) was recorded by ART and LUM, 
ART and PPQ and LUM and DHA while the rest showed no correlation significance p>0.05 with their r values 
lower than 0.1 as shown in table 2 below 
Figure 1: In vitro activities of ART, LUM, DHA and PPQ against Plasmodium falciparum field isolates 
transported in EDTA and in TM 
in vitro activity of the field isolates in EDTA and TM to antimalarials
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The abbreviations E and T represent samples in EDTA and in Transport medium respectively. The medians IC50 
(purple bars) with their interquartile ranges in black for all the drugs 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol.44, 2016 
 
10 
Table 1: Drug susceptibility testing of Plasmodium falciparum isolates in EDTA and TM against a panel of 
antimalarials 
Median IC50 in ng/ml for isolates 
Isolates in EDTA Isolates in (Transport 
medium) TM 
P values of the medians using Mann - 
whitney test (P) 
 Drugs Median  Median   
1 Artemether 4.275 4.887 0.9873 
2 Lumefatrine 5.409 4.007 0.7448 
3 Diydroartemisinin 2.567 1.691 0.6839 
4 Piperaquine 7.887 6.911 0.8153 
 
Table 2: Correlation of in vitro responses of antimalarials drugs against field isolates of Plasmodium 
falciparum in EDTA and TM 
Isolates in EDTA Isolates in (transport medium)TM 
Drug pairs Correlation 
coefficient (r) 
Probability 
P value 
Drug pairs Correlation 
coefficient (r) 
Probability 
P value 
ART - LUM 0.04967 0.3699 ART - LUM 0.1260 0.0225 
ART - DHA 0.123 0.0259 ART - DHA 0.09014 0.1032 
ART - PPQ 0.0262 0.6364 ART - PPQ 0.1834 0.0008 
LUM - DHA 0.1382 0.0122 LUM - DHA 0.1229 0.0261 
LUM - PPQ 0.0584 0.2916 LUM - PPQ 0.0758 0.1709 
DHA -  PPQ 0.1281 0.0203 DHA -  PPQ 0.0372 0.5024 
The correlation coefficient was calculated by Pearson’s correlation coefficient of log IC50 values. 
Probability refers to the significance level of the test (p<0.05). ART- Artemether, LUM - Lumefantrine, DHA - 
Dihydroartemisinin and PPQ – Piperaquine 
 
DISCUSSION 
In vitro drug assays in the field are best perfomed on fresh isolates immediately after collection (Basco, 2004) 
and it’s simpler to perform than culture adapted as others have observed (Akala et al., 2011; Bacon et al., 2007). 
It also reduces concerns on the selection of dominant clones and loss of minor subpopulations (Liu et al., 2008) 
hence consequent misidentification of a population’s susceptibility profile (Mbaisi et al., 2004). However, blood 
samples containing P. falciparum parasites for testing may be stored at collection sites for days transported long 
distances to the laboratory before cultivation (Akala et al., 2011), a factor which could cause failure of growth 
attributed to a prolonged time between the times when samples were collected and when they were tested (Bacon 
et al., 2007) hence reducing the parasites viability to even zero (Basco, 2004). Availability of a medium would 
provide a proper transition from the natural host to an artificial medium and would keep the parasites viable to 
the laboratory for cultivation. This is the first study to report a direct comparison between two anticoagulants, 
evaluating the possible influence of the formulated transport medium (TM) on maintaining parasite viability 
during storage at 4°C against the conventional EDTA anticoagulant. Among the assays, the upper half of the IC50 
was notably higher for all the drugs in both categories, this may reflect greater biological variability among the 
field isolates with the presence of sub populations of drug resistant and sensitive parasites (Jefari et al., 
2004).This factor addressed the fact that some plates produced assays whose curves didn’t calculate an IC50 
because the points could not converge to create an ideal IC50 dose response curve due to the presence of a 
subpopulation in low proportions (10%),  as also evident a study (CO-EM et al., 2009).  
Patient blood samples usually have very different parasitemia, and most drug assays are sensitive to 
variation in parasitemia. (Liu et al., 2008). Parasitaemia estimation in any in vitro assay is highly dependent on 
microscopy therefore variation occurs depending on the expertise of the microscopist in the laboratory. If the 
starting parasitaemia in an assay is mistakably high then much infected parasites would be found in each well of 
the plate leading to an increase in the absorption of drugs, consequently increasing the IC50 levels obtained 
(Geary et al., 1990).This explains the high levels of RFU when curves were plotted against the drug 
concentration in the present study. The vice versa is true such that a very low starting parasitaemia may lead to a 
lack of growth and less IC50 values as reported by Bacon (Bacon et al.,2007). Increasing the number of infected 
erythrocytes leads to higher drug uptake (Basco, 2004) such that there is need for an increased concentration of 
drugs to inhibit growth when numbers of parasites per volume were inoculated (Duraisinngh et al., 1999; 
Gluzman et al., 1987). A cambodian study also confirmed that parasitaemia level is inversely proportional to the 
IC50 values (Suwanna et al., 2013), these previous studies justified the high IC50 values obtained with some 
plates which consequently raised the mean IC50 especially for PPQ in the current study for samples in both 
EDTA and TM since both used the same amount of parasitaemia. 
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DHA was expectedly the most active drug with the least median IC50 values (2.567 and 1.691 in EDTA 
and TM respectively) and ranges in both EDTA and TM samples which still wasn’t significant. This could be 
attributed by the fact that they are few if any reduced susceptibility cases of the drug in the region and generally 
in Kenya, this is in line with a study conducted at the Kenyan coast and emerged the most active drug too (Mwai 
et al.,2009). Higher IC50 values (7.887 in EDTA and 6.911 in TM samples) experienced by PPQ in our data were 
unlikely to represent resistance but probably methodological variability, since these values obtained were way 
below the IC50 values from previous reports from malaria endemic areas (Basco et al., 2007 and Mwai et al., 
2009). In contrary with other studies which have found an IC50 LUM activity of 30nm for more than 95% of 
isolates (Mayxay et al., 2007; Parola et al., 2007; Paradines et al., 2006), our study generated only 24 and 20% 
from samples in EDTA and TM respectively, a clear indication that the activity of the drug which is used as a 
partner to ART for treatment of uncomplicated malaria cases remains high in the region. Encouragingly, our 
ART IC50 data which were 4.27 and 4.88 in EDTA and TM respectively were comparable with those found 
earlier for clinical isolates collected in Cameroon and other African countries where their IC50 values were 
ranging between 3.46 and 5.66nm (Basco and LeBras, 1993; Basco and Ringwald, 2003 and Issaka et al., 2013) 
The inoculum size used in in vitro testing influences the measured in vitro susceptibility to antimalarials, 
therefore resistance can be overestimated when inoculum effects aren’t considered. On the other hand, 
occurrences of cross resistance between antimalarials can also be falsely determined in some cases (Duraisinngh 
et al., 1999). Positive correlation (P<0.05) was observed between DHA and all the tested drugs (ART, LUM and 
PPQ) for samples in EDTA, unlike the same samples in TM where DHA had a correlation significance 
(P=0.0261, r=0.1229) with LUM only while others weren’t. The variation in the cross resistance of DHA in the 
samples in EDTA and TM would have been attributed by the inoculum effect. However, further research need to 
be conducted to rule out possible cross resistance between these drugs in the region. Although, a Kenyan coast 
study which found a positive correlation between DHA and LUM, and also between LUM and PPQ (Mwai et al., 
1999) were in line with the results of the current study.  
 
Conclusion 
This current study makes it explicit that the formulated transport medium holds promise for future use having 
shown similar IC50 results with no significant difference with the samples which were in the EDTA 
anticoagulants tubes. Variations in the positive correlations experienced by DHA is a proof of possible cross 
resistance between this drugs which need further research to elucidate on the finding. 
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